Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment

被引:5
作者
To, Kenneth K. W. [1 ]
Cheung, Ka M. [2 ]
Cho, William C. S. [2 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Room 801N, Lo Kwee Seong Integrated Biomed Sci Bld, Hong Kong, Peoples R China
[2] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
关键词
Triamterene; Cisplatin; Histone deacetylases; Repurposing; Non-small cell lung cancer; DRUG; THERAPY; CELLS; HDACI;
D O I
10.1007/s00432-023-04641-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeCisplatin is the core chemotherapeutic drug used for first-line treatment of advanced non-small cell lung cancer (NSCLC). However, drug resistance is severely hindering its clinical efficacy. This study investigated the circumvention of cisplatin resistance by repurposing non-oncology drugs with putative histone deacetylase (HDAC) inhibitory effect.MethodsA few clinically approved drugs were identified by a computational drug repurposing tool called "DRUGSURV" and evaluated for HDAC inhibition. Triamterene, originally indicated as a diuretic, was chosen for further investigation in pairs of parental and cisplatin-resistant NSCLC cell lines. Sulforhodamine B assay was used to evaluate cell proliferation. Western blot analysis was performed to examine histone acetylation. Flow cytometry was used to examine apoptosis and cell cycle effects. Chromatin immunoprecipitation was conducted to investigate the interaction of transcription factors to the promoter of genes regulating cisplatin uptake and cell cycle progression. The circumvention of cisplatin resistance by triamterene was further verified in a patient-derived tumor xenograft (PDX) from a cisplatin-refractory NSCLC patient.ResultsTriamterene was found to inhibit HDACs. It was shown to enhance cellular cisplatin accumulation and potentiate cisplatin-induced cell cycle arrest, DNA damage, and apoptosis. Mechanistically, triamterene was found to induce histone acetylation in chromatin, thereby reducing the association of HDAC1 but promoting the interaction of Sp1 with the gene promoter of hCTR1 and p21. Triamterene was further shown to potentiate the anti-cancer effect of cisplatin in cisplatin-resistant PDX in vivo.ConclusionThe findings advocate further clinical evaluation of the repurposing use of triamterene to overcome cisplatin resistance.
引用
收藏
页码:7217 / 7234
页数:18
相关论文
共 50 条
[41]   Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer [J].
Dovzhanskiy, Dmitriy I. ;
Arnold, Stefanie M. ;
Hackert, Thilo ;
Oehme, Ina ;
Witt, Olaf ;
Felix, Klaus ;
Giese, Nathalia ;
Werner, Jens .
BMC CANCER, 2012, 12
[42]   Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope? [J].
Mamdani, Hirva ;
Jalal, Shadia, I .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
[43]   Overcome of Cisplatin Resistance in Ovarian Cancer by Combination of Low-intensity Ultrasound and Cisplatin [J].
Kip, Bilgi ;
Aydin, Omer .
CURRENT DRUG DELIVERY, 2023, 20 (09) :1380-1390
[44]   HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat [J].
Zuwala, Kaja ;
Smith, Anton A. A. ;
Tolstrup, Martin ;
Zelikin, Alexander N. .
CHEMICAL SCIENCE, 2016, 7 (03) :2353-2358
[45]   Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer [J].
Li, Zhong-Hua ;
Zhang, Xiao-Bing ;
Han, Xi-Qian ;
Feng, Cong-Ran ;
Wang, Feng-Shan ;
Wang, Peng George ;
Shen, Jie ;
Shi, Yi-Kang .
ONCOLOGY REPORTS, 2013, 30 (01) :499-505
[46]   The Rationale for Repurposing Sildenafil for Lung Cancer Treatment [J].
Keats, Theodore ;
Rosengren, Rhonda J. ;
Ashton, John C. .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (03) :367-374
[47]   Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFRWT human lung cancer [J].
Li, Rui ;
Zhao, Weiheng ;
Jin, Chen ;
Xiong, Huihua .
BIOORGANIC CHEMISTRY, 2023, 135
[48]   Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid [J].
Rikiishi, Hidemi ;
Shinohara, Fumiaki ;
Sato, Tomonori ;
Sato, Yoshitaro ;
Suzuki, Maiko ;
Echigo, Seishi .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (05) :1181-1188
[49]   MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin [J].
Konoshenko, Maria ;
Lansukhay, Yuriy ;
Krasilnikov, Sergey ;
Laktionov, Pavel .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
[50]   Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus [J].
Ellerhoff, Tim Patrick ;
Berchtold, Susanne ;
Venturelli, Sascha ;
Burkard, Markus ;
Smirnow, Irina ;
Wulff, Tanja ;
Lauer, Ulrich M. .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (05) :1931-1944